Timothée Olivier, Medical oncologist at the Oncology Division of Geneva University, shared on X:
“NATALEE trial: 3 years of adjuvant ribociclib in early breast cancer:
iDFS benefit
OS benefit
Concerns: Informative censoring? + others!
-> it got an “A”?
Don’t stop at scores – dig deeper into the data to better inform shared decision-making.”
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Authors: Alyson Haslam, Sruthi Ranganathan, Vinay Prasad, Timothée Olivier
